Description of a new hepatitis C risk assessment tool

Archives of Internal Medicine

Volumn 165, Issue 17, 2005, Pages 2013-2018

  Nguyen, Minhhuyen T ^a   Herrine, Steven K ^b   Laine, Christine A ^b   Ruth, Karen ^a   Weinberg, David S ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ILLICIT DRUG;

ADULT; AGED; ARTICLE; BLOOD DONOR; DEMOGRAPHY; EXPOSURE; FEMALE; GENERAL PRACTICE; HEALTH INSURANCE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MALE; MEDICAL PRACTICE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTITUTION; QUESTIONNAIRE; RISK ASSESSMENT; SELF REPORT; SEROLOGY; SEXUAL BEHAVIOR; SOCIAL ASPECT; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HEPATITIS C; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PHILADELPHIA; RISK ASSESSMENT; SELF ASSESSMENT (PSYCHOLOGY);

EID: 25444476077     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.17.2013     Document Type: Article

References (27)

1. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331-338.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26:62S-65S.
3. Dubois F, Francois M, Mariotte N, et al. Serum alanine aminotransferase measurement as a guide to selective testing for hepatitis C during medical checkup. J Hepatol. 1994;21:837-841.
4. Piton A, Poynard T, Imbert-Bismut F, et al; MULTIVIRC Group. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology. 1998;27:1213-1219.
5. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology. 2002;36:S121-S127.
6. McHutchison JG, Gordon SC, Schiff ER, et al; Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-1492.
7. Donahue JG, Nelson KE, Munoz A, et al. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol. 1991;134:1206-1211.
8. Murphy EL, Bryzman S, Williams AE, et al. Demographic determinants of hepatitis C virus seroprevalence among blood donors. JAMA. 1996;275:995-1000.
9. McQuillan G, Alter MJ, Moyer L, Lambert S, Margolis H. A population based serological study of hepatitis C infection in the United States. In: Rizzetto M, Purcell R, Gerin G, Verme G, eds. Viral Hepatitis and Liver Disease. Turin, Italy: Edizioni Minerva Medica; 1997:267-270.
10. Kaldor JM, Archer GT, Buring ML, et al. Risk factors for hepatitis C virus infection in blood donors: a case-control study. Med J Aust. 1992;157:227-230.
11. Lapane KL, Jakiche AF, Sugano D, Weng CS, Carey WD. Hepatitis C infection risk analysis: who should be screened? comparison of multiple screening strategies based on the National Hepatitis Surveillance Program. Am J Gastroenterol. 1998;93:591-596.
12. Friedman SR, Jose B. Hepatitis C transmission and the underreporting of stigmatized behaviors. Sex Transm Dis. 1998;25:220-221.
13. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334:1691-1696.
14. Navarro VJ, St Louis TE, Bell BP. Identification of patients with hepatitis C virus infection in New Haven County primary care practices. J Clin Gastroenterol. 2003;36:431-435.
15. Boaz K, Fiore AE, Schrag SJ, Gonik B, Schulkin J. Screening and counseling practices reported by obstetrician-gynecologists for patients with hepatitis C virus infection. Infect Dis Obstet Gynecol. 2003;11:39-44.
16. Rocca LG, Yawn BP, Wollan P, Kim WR. Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med. 2004;2:116-124.
17. US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med. 2004;140:462-464.
18. Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:465-479.
19. O'Brien JM, Kruzel KE, Wandell MG, Vinogradov IV, Sheagren JN, Frank AP. Detection of hepatitis C antibody with at-home collection kits using an innovative laboratory algorithm. Infect Dis Clin Pract. 2001;10:474-480.
20. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med. 2004;141:715-717.
21. Management of hepatitis C: 2002. NIH Consens State Sci Statements. 2002;19:1-46.
22. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1-39.
23. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
24. Kaur S, Rybicki L, Bacon BR, Gollan JL, Rustgi VK, Carey WD; National Hepatitis Surveillance Group. Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results of the National Hepatitis Screening Survey. Hepatology. 1996;24:979-986.
25. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut. 1999;44:874-880.
26. Dubois F, Desenclos JC, Mariotte N, Goudeau A; Collaborative Study Group. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology. 1997;25:1490-1496.
27. Banwell C, Bammer G, Main N, Gifford SM, O'Brien M. Disturbingly low levels of contraception among women living with hepatitis C. Aust N Z J Public Health. 2003;27:620-626.